A significant proportion of UK community pharmacy owners are actively considering an exit in 2026. Years of funding pressure, the chronic gap between CPCF income and the true cost of delivering N HS pharmacy services, rising staffing costs following the April 2026 employer NIC and National Living Wage increases, and the relentless operational demands of running a pharmacy through a sustained closure wave across the sector have combined to push many owners toward a decision they once thought was years away. For anyone selling pharmacy UK 2026, tax planning now needs to happen before a buyer is found, not after terms are agreed.
At the same time, the tax cost of selling has just increased Business Asset Disposal Relief the relief that reduces Capital Gains Tax on qualifying business disposals, rose to 18% from 6 April 2026, up from 14% in 2025/26 and 10% before that. On a £1 million qualifying gain, that increase from 14% to 18% represents an additional £40,000 of tax compared to a disposal completed before the rate change. For pharmacy owners who have built substantial goodwill value over years or decades of trading, this rate increase is not a footnote, it materially changes the net proceeds of a sale.
This guide sets out the financial and tax planning considerations that every pharmacy owner contemplating a sale needs to understand before they exchange contracts. It covers the BADR rate change and what it means in practice, the difference between an asset sale and a share sale, how pharmacy goodwill is valued and taxed, the financial due diligence steps that strengthen your negotiating position, and the planning actions that should be taken well before a buyer is found, not after heads of terms have been signed.
Selling pharmacy UK 2026: the BADR rate change and what it actually costs you now
Business Asset Disposal Relief reduces the CGT rate on qualifying business disposals to a flat rate, applied to the first £1 million of lifetime qualifying gains for each individual. The rate has changed twice in two years, 10% for disposals before 6 April 2025, 14% for disposals between 6 April 2025 and 5 April 2026, and 18% for any disposal completed on or after 6 April 2026.
For a pharmacy owner with a qualifying gain of £1 million, a realistic figure for a long established, profitable single site pharmacy with substantial goodwill, the tax payable under BADR has risen from £100,000 at the original 10% rate to £180,000 at the current 18% rate. That is an £80,000 increase in tax on an identical gain, purely as a result of timing.
Gains above the £1 million lifetime limit do not qualify for BADR at all and are taxed at the standard CGT rates, 18% within the basic rate band and 24% above it. For a pharmacy owner with a gain of £1.5 million, the first £1 million is taxed at 18% (£180,000) and the remaining £500,000 at the standard higher rate of 24% (£120,000), a combined CGT bill of £300,000.
BADR qualifying conditions require that you have owned and been actively involved in the business, as a sole trader, partner, or as a director holding at least 5% of the shares and voting rights, for a continuous period of at least two years immediately before the sale. Missing this two year threshold by even a few weeks disqualifies the entire gain from BADR, pushing it to the standard CGT rates instead. If you are planning a sale and are close to the two year threshold on any aspect of your ownership or shareholding structure, the timing of completion relative to that anniversary date deserves careful attention.
Asset sale or share sale: the decision that shapes everything else
For pharmacy owners operating through a limited company, which describes the majority of established community pharmacies, one of the first and most consequential decisions in any sale process is whether the transaction will be structured as a sale of company shares or a sale of the company's underlying assets and trade.
A share sale means the buyer purchases the shares in your limited company directly from you as the shareholder. The company itself, including its NHS contract, its assets, its liabilities, and its trading history, continues to exist, only the ownership changes. For the seller, this is typically the more tax efficient route: you pay CGT once, personally, on the gain arising from the disposal of your shares, with BADR available to reduce the rate to 18% on qualifying gains up to the £1 million lifetime limit.
An asset sale means the company itself sells its trade, goodwill, fixtures, and stock to the buyer, while you retain ownership of the now empty company shell or wind it down separately. This route frequently creates a double taxation problem for sellers: the company first pays Corporation Tax on the gain arising from the sale of its assets, at 25% for profits above £250,000, and you then face a second layer of tax when you extract the remaining cash from the company, whether as dividends taxed at up to 41.35% from April 2026 or through a Members' Voluntary Liquidation distribution which can itself qualify for BADR at 18% if structured correctly.
Why buyers often prefer asset sales regardless: buyers frequently prefer to purchase assets rather than shares because an asset purchase allows them to claim capital allowances on the assets acquired and avoids inheriting any historic liabilities, warranties, or contractual obligations buried in the company's history. This creates a genuine tension in negotiations, what is most tax efficient for you as the seller is often what the buyer is most reluctant to agree to. Many pharmacy sale negotiations include a price adjustment specifically to compensate the seller for the less favourable tax treatment of an asset sale, where the buyer insists on that structure.
Deciding which structure to pursue, and how hard to negotiate for your preferred structure, needs to happen before you go to market, not once an offer is on the table. Our pharmacy accountants model both structures against your specific shareholding, your company's balance sheet, and your personal BADR position to identify which route delivers the better net outcome before negotiations begin.
How pharmacy goodwill is valued and why it drives the tax outcome
Goodwill is, in almost every pharmacy sale, the single largest chargeable asset and therefore the largest source of CGT liability. Understanding how it is valued, and how its tax treatment differs depending on how it arose, is essential before you enter negotiations.
Self generated goodwill, the goodwill you have built up yourself over years of trading, rather than purchased from a previous owner, has a base cost of nil for CGT purposes. This means the entire value attributed to goodwill in the sale price is a chargeable gain, with no deduction for the years of effort, investment, or risk that created it. BADR can reduce the rate to 18% on this gain, but it does not reduce the gain itself.
For pharmacies, goodwill value is typically derived from the NHS contract relationship, dispensing volume and patient loyalty, the retained margin position, private and OTC retail performance, and increasingly in 2026, the value attributed to commissioned services income such as Pharmacy First, the Pharmacy Contraception Service, and the new independent prescribing infrastructure payment. A pharmacy with strong, diversified service income beyond core NHS dispensing typically commands a higher goodwill multiple than one reliant purely on dispensing volume, because the income is seen as more resilient to future CPCF funding pressure.
Valuation methodologies commonly applied to pharmacy goodwill include a multiple of maintainable earnings, typically applying a multiplier to normalised EBITDA, adjusted for owner's drawings and any non recurring items, and less commonly an asset based or super profits approach. There is no single prescribed method, and HMRC expects valuations to be reasonable and supportable rather than conforming to one specific formula. Given the size of the figures typically involved in a pharmacy sale, an independent, defensible valuation prepared by someone who understands both pharmacy economics and HMRC's expectations is essential, not only to support the price you negotiate with a buyer, but to withstand any HMRC challenge to the CGT computation after the event.
The incorporation trap. If you originally operated your pharmacy as a sole trader and later incorporated, transferring the self generated goodwill into your limited company, that transfer was itself a disposal at market value for CGT purposes, though Incorporation Relief may have deferred the gain into the base cost of the shares you received. Critically, the company is then unable to amortise that goodwill for Corporation Tax purposes where you hold 5% or more of the shares, because the goodwill was acquired from a related party. If your pharmacy has been through an incorporation in the past, the historic goodwill transfer needs to be reviewed as part of any current sale planning, as it directly affects your base cost and the gain calculation on the eventual sale of your shares.
Financial due diligence: what buyers will scrutinise
Before any pharmacy sale completes, the buyer's due diligence process will examine every aspect of the business's financial health. Preparing for this scrutiny in advance, rather than reacting to it during a live transaction, materially improves both your negotiating position and the speed of completion.
NHS contract and NHSBSA payment history. Buyers will request and review your NHSBSA payment schedules for the preceding two to three years, checking for consistency, any unresolved clawbacks, and the trajectory of dispensing volume. Unresolved discrepancies between your management accounts and the NHSBSA schedules are a red flag that buyers will use to justify a reduced offer or extended warranties.
Margin and Category M exposure. Buyers will assess your historic margin performance against the sector wide Category M allowance, looking for evidence that the pharmacy has managed its purchasing efficiently. A pharmacy with a strong, well documented purchasing strategy and evidence of consistent margin capture is a more attractive proposition than one where margin performance has been volatile or poorly tracked.
Staffing cost structure and compliance. Following the April 2026 employer NIC and NLW increases, buyers will model your staffing cost base forward, checking that payroll is correctly structured, that the Employment Allowance has been correctly claimed, and that there are no outstanding HMRC compliance issues relating to PAYE or NIC. Any unresolved payroll compliance gaps identified during due diligence will either reduce the offer or require specific warranties and indemnities in the sale agreement.
Lease terms and premises. Where you operate from leased premises, the remaining lease term, any rent review clauses, and the landlord's consent requirements for assignment of the lease or the NHS pharmacy contract location are all reviewed closely, as the value of the pharmacy is closely tied to its specific location and the security of tenure at that location.
VAT partial exemption position. If your pharmacy has any standard rated income, cosmetic services, retail sales above the dispensing exemption, your VAT partial exemption calculation will be reviewed for accuracy and consistency. Our VAT specialist team prepares a clean, defensible partial exemption history as part of pre sale preparation, well in advance of any due diligence request.
Carrying out an internal financial review against all of these areas, ideally twelve to twenty four months before you intend to go to market, allows time to correct any issues that would otherwise depress the sale price or extend the negotiation period once a buyer is engaged.
Capital allowances: the often overlooked value in a pharmacy sale
Pharmacy premises typically contain substantial fixtures and fittings, dispensing robots and automation equipment, refrigeration units, point of sale systems, shopfitting, and consultation room fit outs, that qualify for capital allowances. The treatment of these allowances on a sale is frequently mishandled, to the detriment of either the seller or the buyer.
Where the pharmacy is sold as a share sale, the company retains its existing capital allowances pool unchanged, the buyer simply inherits the pool balance along with the company. Where the pharmacy is sold as an asset sale, a Section 198 election between buyer and seller is required to agree the apportionment of the sale price between qualifying plant and machinery for which the seller faces a balancing charge or allowance, and the buyer gains a new capital allowances pool and other elements of the price such as goodwill and property which are not affected by the election.
As covered in our guide on the Writing Down Allowance reduction to 14% pharmacies with substantial existing pool balances from automation and refrigeration investment have already seen their annual WDA relief reduce from April 2026. On a sale, the unrelieved pool balance and the agreed apportionment under any Section 198 election directly affect both your balancing charge calculation and the buyer's future capital allowances position, making this a genuine negotiation point that should be addressed explicitly in the sale agreement, not left for accountants to resolve after completion.
Selling pharmacy UK 2026 pre sale planning: what to do 12 to 24 months before you sell
The most effective tax planning for a pharmacy sale happens well before a buyer is identified, not in the weeks before completion, when most of the available planning options have already closed off.
Confirm your BADR eligibility position now. Review your shareholding structure, your length of ownership, and your role within the business against the BADR qualifying conditions. If there are any gaps, for example, a recent change in shareholding structure that resets the two year clock, address them as early as possible.
Review your business's trading status. BADR and several other reliefs require the business to be a trading company, not an investment company. If your pharmacy company holds significant non trading assets, excess cash retained well beyond working capital needs, an investment property, or other non trading investments, these can jeopardise your BADR eligibility on the whole disposal. Extracting excess non trading assets from the company well in advance of a sale, through dividends or pension contributions, is a standard and effective preparatory step.
Consider spousal shareholdings. If you intend to involve a spouse or civil partner in the ownership structure to make use of multiple BADR lifetime allowances and multiple CGT annual exempt amounts, these transfers need to happen well in advance, satisfying the two year ownership and involvement rule before the anticipated sale date. A transfer made shortly before a sale will not qualify and may itself trigger an unwanted tax event.
Model pension contributions from sale proceeds. Making substantial pension contributions either in the lead up to a sale, reducing taxable profits and adjusted income in the years before disposal, or from the sale proceeds themselves can shelter significant value from tax, subject to your available annual allowance and any carry forward from prior years. This is a genuinely valuable planning tool that is frequently left unconsidered until after a sale has already completed, by which point the opportunity has often passed.
Get an independent goodwill valuation prepared in advance. A defensible, professionally prepared valuation strengthens your negotiating position with a buyer and provides the supporting evidence HMRC expects if your CGT computation is ever queried.
Clear answers to the most common questions pharmacy owners ask about CGT, BADR, asset sales, share sales and pre sale planning before selling a pharmacy.
Frequently asked questions
My pharmacy is owned through a limited company and I am the sole shareholder. does the timing of my sale relative to the tax year matter?
Yes, in several ways. The BADR rate that applies is determined by the date of completion, not the date negotiations began, a disposal completing on 5 April 2026 attracts the 14% rate, while completion one day later on 6 April 2026 attracts 18%. Beyond the BADR rate itself, your other income in the tax year of sale also affects your overall CGT position on any gain above the BADR lifetime limit, since the standard rate that applies depends on whether your total income and gains fall within the basic or higher rate band. If you have flexibility over the exact completion date, modelling the tax outcome under different timing scenarios, in conjunction with your annual CGT exempt amount of £3,000 for 2026/27, is a worthwhile exercise before finalising the date.
I have already used some of my BADR lifetime allowance on a previous business sale. how does this affect a pharmacy sale now?
The £1 million BADR lifetime limit applies per individual across all qualifying disposals made during your lifetime, not per business. If you have previously claimed BADR on an earlier disposal, for example, the sale of a different pharmacy, or any other qualifying business, that amount is deducted from your remaining lifetime allowance. Any gain on your current pharmacy sale that falls within your remaining BADR capacity is taxed at 18%; any gain above your remaining capacity is taxed at the standard CGT rates of 18% or 24% depending on your income tax band. Calculating your precise remaining BADR capacity before entering sale negotiations is essential to accurately forecast your net proceeds.
The buyer wants to structure the deal as an asset sale. can I still claim BADR?
It depends on exactly how the proceeds reach you personally. If your company sells its assets and you then extract the proceeds as dividends, BADR does not apply to dividend income at all, dividends are taxed at the dividend rates up to 41.35% from April 2026, with no relief. If instead the company is wound up through a Members' Voluntary Liquidation following the asset sale, the distribution to you as a capital distribution can qualify for BADR at 18%, provided the underlying conditions are met. The route by which proceeds are extracted from the company after an asset sale therefore has a very significant effect on your final tax position, and this should be modelled and agreed before the asset sale structure is accepted, not decided afterwards.
How long does a typical pharmacy sale take from agreeing heads of terms to completion?
This varies considerably depending on the complexity of the transaction, but a typical community pharmacy sale, particularly one involving an NHS contract that requires regulatory notification and, where relevant, CQC or GPhC considerations, commonly takes four to nine months from heads of terms to completion. Financial due diligence, the negotiation of the sale and purchase agreement, and any third party consents required for an NHS contract assignment are usually the longest stages. Beginning your financial preparation well before you go to market, ideally with a clean set of management accounts, a defensible goodwill valuation, and your BADR position already confirmed, significantly shortens this timeline once a buyer is found.
Should I get a tax specialist involved before I even start looking for a buyer, or only once an offer is on the table?
Before. The most valuable tax planning opportunities, confirming BADR eligibility, removing non trading assets from the company, considering spousal shareholdings, obtaining a defensible goodwill valuation, and reviewing your historic capital allowances and any incorporation history, all require lead time and, in several cases, cannot be implemented retrospectively once a sale is already in progress. Engaging a specialist who understands pharmacy economics specifically, rather than a generalist business sale adviser, twelve to twenty four months before you intend to sell gives you the maximum range of planning options and the strongest negotiating position when a buyer is eventually found. Contact our team to discuss your specific position well in advance of any sale process.
Summary: the planning window is now, not when you find a buyer
Selling a pharmacy in 2026 carries a meaningfully higher tax cost than it did even twelve months ago, purely as a result of the BADR rate increase to 18%. Against that backdrop, the financial and tax planning decisions that protect your net proceeds, the asset sale versus share sale structure, your BADR eligibility, your company's trading status, your capital allowances position, and the timing of completion, all need lead time to implement correctly.
The pharmacy owners who achieve the best outcome from a sale are those who treat the eighteen to twenty four months before going to market as an active planning period, not a waiting period.
- Confirm your BADR eligibility before entering negotiations.
- Model the difference between an asset sale and a share sale.
- Review your company's trading status and non trading assets.
- Prepare a defensible independent goodwill valuation.
- Resolve capital allowances and VAT history before due diligence begins.
- Clean up management accounts before going to market.
- Plan early enough to protect the after tax value of your sale proceeds.
Clean management accounts, a defensible independent goodwill valuation, a confirmed BADR position, and a resolved capital allowances and VAT history all strengthen your position with a buyer and protect the after tax value of years of work building the business.
If you are considering selling your pharmacy, whether the timeline is months or years away, contact our team to begin the financial planning process.
Pharmacy Accountants Pharmacy Business Expenses Starting Your Own Pharmacy Financial Setup Guide Writing Down Allowances Drop to 14%
Planning to sell your pharmacy?
If you are considering selling your pharmacy, whether the timeline is months or years away, contact our team to begin the financial planning process before you exchange.